drugset
drugset / Trial / NCT07847359

Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial

NCT07847359 ↗

Phase 2 Recruiting 28 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

To explore the efficacy and safety of cryoablation combined with hepatic arterial infusion of iparomlimab and tuvonralimab, intravenous dacarbazine, and oral lenvatinib in patients with liver metastases from malignant melanoma.

Timeline

Start
2026-10-01
Primary completion
2028-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule 850 mg/m2 Intravenous
Subject Dacarbazine Small molecule 1000 mg/m2 Intravenous
Subject Iparomlimab and tuvonralimab Protein / enzyme biologic 7.5 mg/kg Other
Subject Lenvatinib Small molecule 8 mg Oral

Indications

cutaneous melanoma